Merck Stock Rises Despite 70th Rank in Trading Volume

On June 10, 2025, Merck's trading volume reached $1.032 billion, marking a 28.95% decrease from the previous day. The stock ranked 70th in terms of trading volume for the day. Merck's stock price rose by 2.55%, marking the third consecutive day of gains, with a total increase of 4.81% over the past three days.

Merck recently announced positive topline results from the first two Phase 3 CORALreef trials evaluating Enlicitide Decanoate for the treatment of adults with hyperlipidemia. The trials, CORALreef HeFH and CORALreef AddOn, demonstrated statistically significant and clinically meaningful reductions in LDL-C levels for Enlicitide compared to placebo.

Additionally, Merck received approval from the U.S. Food and Drug Administration (FDA) for ENFLONSIA™ (clesrovimab-cfor), a preventive monoclonal antibody designed to protect infants against respiratory syncytial virus (RSV) lower respiratory tract disease. ENFLONSIA is the first and only RSV preventive option administered to infants using the same dose regardless of weight, providing direct, rapid, and durable protection through 5 months, a typical RSV season.

ENFLONSIA's approval is based on results from the pivotal Phase 2b/3 CLEVER trial, which showed a 60.5% reduction in the incidence of RSV-associated medically attended lower respiratory infections and an 84.3% reduction in RSV-associated hospitalizations through 5 months. The approval is also supported by results from the Phase 3 SMART trial, which evaluated the safety and efficacy of ENFLONSIA versus palivizumab in infants at increased risk for severe RSV disease.